<table cellpadding="0pt" width="99.96%" xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<col width="16%"></col>
<col width="84%"></col>
<tbody>
<tr>
<td colspan="2" stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="bold">Inhibitors of CYP3A4</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of OTFC and CYP3A4 inhibitors can increase the plasma concentration of fentanyl, resulting in increased or prolonged opioid effects, particularly when an inhibitor is added after a stable dose of OTFC is achieved <content stylecode="italics">[se</content>
<content stylecode="italics">e Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be">5.3</linkhtml>
</content>
<content stylecode="italics">)]</content>.</paragraph>
<paragraph>After stopping a CYP3A4 inhibitor, as the effects of the inhibitor decline, the fentanyl plasma concentration will decrease <content stylecode="italics">[</content>
<content stylecode="italics">see Clinical Pharmacology (</content>
<content stylecode="italics">
<linkhtml href="#i4i_pharmacokinetics_id_ebfe50d2-6256-44d9-85dc-c1608b418ac8">12.3</linkhtml>
</content>
<content stylecode="italics">)]</content>, resulting in decreased opioid efficacy or a withdrawal syndrome in patients who had developed physical dependence to fentanyl.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>If concomitant use is necessary, consider dosage reduction of OTFC until stable drug effects are achieved. Monitor patients for respiratory depression and sedation at frequent intervals. If a CYP3A4 inhibitor is discontinued, consider increasing the OTFC dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Macrolide antibiotics (e.g., erythromycin), azole-antifungal agents (e.g., ketoconazole), protease inhibitors (e.g., ritonavir), grapefruit juice.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="bold">CYP3A4 Inducers</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of OTFC and CYP3A4 inducers can decrease the plasma concentration of fentanyl <content stylecode="italics">[</content>
<content stylecode="italics">see Clinical Pharmacology (</content>
<content stylecode="italics">
<linkhtml href="#i4i_pharmacokinetics_id_ebfe50d2-6256-44d9-85dc-c1608b418ac8">12.3</linkhtml>
</content>
<content stylecode="italics">)]</content>, resulting in decreased efficacy or onset of a withdrawal syndrome in patients who have developed physical dependence to fentanyl <content stylecode="italics">[</content>
<content stylecode="italics">see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#i4i_section_id_6b0f9ad8-fdbe-4f32-92c1-a012f09eb7be">5.3</linkhtml>
</content>
<content stylecode="italics">)]</content>.</paragraph>
<paragraph>After stopping a CYP3A4 inducer, as the effects of the inducer decline, the fentanyl plasma concentration will increase <content stylecode="italics">[</content>
<content stylecode="italics">see Clinical Pharmacology (</content>
<content stylecode="italics">
<linkhtml href="#i4i_pharmacokinetics_id_ebfe50d2-6256-44d9-85dc-c1608b418ac8">12.3</linkhtml>
</content>
<content stylecode="italics">)]</content>, which could increase or prolong both the therapeutic effects and adverse reactions, and may cause serious respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>If concomitant use is necessary, consider increasing the OTFC dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. If a CYP3A4 inducer is discontinued, consider OTFC dosage reduction and monitor for signs of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Rifampin, carbamazepine, phenytoin</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Benzodiazepines and Other Central Nervous System (CNS) Depressants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Due to additive pharmacologic effect, the concomitant use of benzodiazepines or other CNS depressants including alcohol, increases the risk of respiratory depression, profound sedation, coma, and death.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients closely for signs of respiratory depression and sedation <content stylecode="italics">[see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#i4i_section_id_9818bbf6-fc17-4204-a05f-c41402041285">5.4</linkhtml>
</content>
<content stylecode="italics">)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Benzodiazepines and other sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, alcohol.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Serotonergic Drugs</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of opioids with other drugs that affect the serotonergic neurotransmitter system has resulted in serotonin syndrome <content stylecode="italics">[see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</linkhtml>
</content>
<content stylecode="italics">)]</content>.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment. Discontinue OTFC if serotonin syndrome is suspected.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), tricyclic antidepressants (TCAs), triptans, 5-HT3 receptor antagonists, drugs that affect the serotonin neurotransmitter system (e.g., mirtazapine, trazodone, tramadol), monoamine oxidase (MAO) inhibitors (those intended to treat psychiatric disorders and also others, such as linezolid and intravenous methylene blue).</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Monoamine Oxidase Inhibitors (MAOIs)</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>MAOI interactions with opioids may manifest as serotonin syndrome <content stylecode="italics">[se</content>
<content stylecode="italics">e Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#inv-80726b26-6050-4911-b26b-bdc2f5fd4dc9">5.10</linkhtml>
</content>
<content stylecode="italics">)] </content>or opioid toxicity (e.g., respiratory depression, coma) <content stylecode="italics">[</content>
<content stylecode="italics">see Warnings and Precautions (</content>
<content stylecode="italics">
<linkhtml href="#inv-c65775f0-7877-4d35-a894-db3f0c991184">5.1</linkhtml>
</content>
<content stylecode="italics">)].</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The use of OTFC is not recommended for patients taking MAOIs or within 14 days of stopping such treatment.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Phenelzine, tranylcypromine, linezolid</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Mixed Agonist/Antagonist and Partial Agonist Opioid Analgesics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>May reduce the analgesic effect of OTFC and/or precipitate withdrawal symptoms.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Avoid concomitant use.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Examples:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Butorphanol, nalbuphine, pentazocine, buprenorphrine</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Muscle Relaxants</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Fentanyl may enhance the neuromuscular blocking action of skeletal muscle relaxants and produce an increased degree of respiratory depression.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Monitor patients for signs of respiratory depression that may be greater than otherwise expected and decrease the dosage of OTFC and/or the muscle relaxant as necessary.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="bold">Diuretics</content>
</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Opioids can reduce the efficacy of diuretics by inducing the release of antidiuretic hormone.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Monitor patients for signs of diminished diuresis and/or effects on blood pressure and increase the dosage of the diuretic as needed.</paragraph>
</td>
</tr>
<tr>
<td colspan="2" stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>Anticholinergic Drugs</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>
<content stylecode="italics">Clinical Impact:</content>
</paragraph>
</td>
<td stylecode="Rrule Lrule Toprule Botrule " valign="top">
<paragraph>The concomitant use of anticholinergic drugs may increase risk of urinary retention and/or severe constipation, which may lead to paralytic ileus.</paragraph>
</td>
</tr>
<tr>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>
<content stylecode="italics">Intervention:</content>
</paragraph>
</td>
<td stylecode="Rrule Botrule Lrule Toprule " valign="top">
<paragraph>Monitor patients for signs of urinary retention or reduced gastric motility when OTFC is used concomitantly with anticholinergic drugs.</paragraph>
</td>
</tr>
</tbody>
</table>